Ozempic has become the most recognized weight loss drug in the world, but its list price of $998 per month puts it out of reach for millions of Americans. If you do not have insurance that covers it — or if your plan requires a steep copay — that number is a dealbreaker. The good news is that several legitimate alternatives now exist that use the same active ingredient or work through the same mechanism, often at a fraction of the cost. For a full Ozempic cost breakdown, we recommend checking the latest pricing data before making any decisions.
Here are five alternatives worth considering in 2026, along with what each one actually costs and how it compares to brand-name Ozempic.
1. Compounded Semaglutide ($99 to $299 per Month)
Compounded semaglutide is the same active ingredient found in Ozempic — semaglutide — prepared by licensed compounding pharmacies rather than manufactured by Novo Nordisk. These pharmacies are permitted to compound semaglutide under FDA regulations when the brand-name drug is in shortage or when a patient has a specific medical need that the commercial product does not meet.
Pricing typically falls between $99 and $299 per month depending on the provider and dosage. The medication is delivered as a subcutaneous injection, just like Ozempic, and the dosing schedule is usually weekly. The key trade-off is that compounded versions are not FDA-approved as finished products, which means quality can vary between pharmacies. Reputable telehealth providers work exclusively with 503B outsourcing facilities that are FDA-inspected and follow current good manufacturing practices. If you go this route, verify that the pharmacy holds 503B accreditation.
2. Wegovy (FDA-Approved Semaglutide for Weight Loss)
Wegovy is the FDA-approved version of semaglutide specifically indicated for chronic weight management. It contains the same molecule as Ozempic but at higher doses optimized for weight loss rather than blood sugar control. Clinical trials showed an average weight loss of 15 to 17 percent of body weight over 68 weeks.
The list price for Wegovy is $1,349 per month, which is actually higher than Ozempic. However, Novo Nordisk offers a savings card that can bring the cost down to as low as $0 for commercially insured patients. For patients without insurance, the savings card reduces the price to $500 per month for the first three months. The real advantage of Wegovy over Ozempic is that insurers are more likely to cover it for weight loss since it carries the FDA-approved indication. If your insurance covers weight loss medications, Wegovy may end up costing less out of pocket than Ozempic prescribed off-label.
3. Foundayo (Orforglipron) — $149 per Month, No Injection
Foundayo is the newest entry on this list, and it changes the equation significantly. Approved by the FDA on April 1, 2026, orforglipron is the first oral GLP-1 receptor agonist approved for weight loss. It is a daily pill — no injection, no fasting requirement, and no special storage needed. Eli Lilly priced it at $149 per month through their LillyDirect pharmacy, with a $25 copay card available for commercially insured patients.
Clinical trials showed 12.4 percent average weight loss at the highest dose over 72 weeks. That is somewhat less than injectable semaglutide, but for patients who refuse needles or struggle with injection-related side effects, Foundayo removes the biggest barrier to starting treatment. The convenience factor alone makes this a compelling alternative for a large segment of patients.
4. Medicare Coverage at $50 per Month (Starting July 2026)
For the 67 million Americans on Medicare, a major shift is coming. Starting July 1, 2026, the Medicare GLP-1 Bridge Program will cover Wegovy, Zepbound, and Foundayo under Part D with a $50 monthly copay cap. This is the first time Medicare has covered any anti-obesity medication, and it makes GLP-1 therapy accessible to seniors who have been locked out of treatment due to cost.
Eligibility requires a BMI of 30 or greater, or 27 or greater with a weight-related comorbidity like type 2 diabetes or hypertension. Prior authorization from a prescribing physician is required. The Bridge Program runs through December 2026, with permanent formulary integration expected in 2027. If you are on Medicare and have been waiting for coverage, this is the window to act.
5. Online Telehealth Programs ($149 to $399 per Month, All-Inclusive)
The telehealth model for GLP-1 prescriptions has matured significantly. Dozens of online providers now offer bundled programs that include the medication itself, physician consultations, ongoing monitoring, and sometimes nutritional coaching — all for a single monthly fee. Prices range from $149 to $399 per month depending on the medication and level of support.
The best programs include licensed physicians who manage dose titration, pharmacies that ship directly to your door, and patient support teams that help with insurance appeals and side effect management. The worst programs cut corners on prescriber quality and use unvetted compounding sources. The difference matters enormously. We have reviewed and independently ranked 32 GLP-1 providers independently ranked to help you tell the difference.
Which Alternative Is Right for You?
The right choice depends on your insurance situation, comfort with injections, and budget. If you have commercial insurance, start by checking whether Wegovy or Foundayo is covered under your plan. If you are uninsured or underinsured, compounded semaglutide through a reputable telehealth provider offers the best value. If you are on Medicare, wait for the Bridge Program in July and get your prior authorization paperwork started now.
Regardless of which path you take, do your research on the provider. Not all telehealth platforms and pharmacies are equal. For a comprehensive comparison of options, see our Ozempic alternatives guide which covers pricing, safety, and provider quality in detail.
The era of Ozempic being the only option — and $998 being the only price — is over. Legitimate alternatives exist, and they are more accessible than ever in 2026.